Shail M Govani1,2,3, Mohamed Noureldin1,4, Peter D R Higgins1, Michele Heisler1,3,4, Sameer D Saini1,3,4, Ryan W Stidham1, Jennifer F Waljee3,5, Akbar K Waljee1,3,4. 1. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. 2. Veterans Affairs (VA) Ann Arbor Healthcare System, Ann Arbor, Michigan, USA. 3. Institute of Health Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA. 4. Center for Clinical Management Research, Veterans Affairs (VA) Ann Arbor Healthcare System, Ann Arbor, Michigan, USA. 5. Department of Plastic Surgery, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
OBJECTIVES: In patients with inflammatory bowel disease (IBD) using biological therapy, non-adherence leads to anti-drug antibody formation and reduced effectiveness. Little is known about the optimal level of adherence in IBD patients on biologic therapy. We aimed to identify the association between adherence and disease flare and determine an optimal level of adherence. METHODS: We analyzed claims data for IBD patients prescribed adalimumab (ADA) and certolizumab (CZP) from the Truven Health MarketScan Commercial Claims and Encounters database from 2009 to 2013. Adherence was calculated using the medication possession ratio (MPR) from initiation until flare occurrence. A disease flare was defined as any hospitalization or new steroid prescription>90-days after drug initiation. The optimal MPR was determined using log-rank testing. The association between the optimal MPR and flare was assessed using multivariable Cox-Proportional hazards ratio. RESULTS: There were 6,048 patients who were prescribed ADA (n=5,325) or CZP (n=723) for IBD. The average age was 41 years (±15) and 54% were female. The optimal MPR identified was 0.86 for ADA and 0.87 for CZP; 24% of the patients were below this level. Adjusting for age, gender, and concomitant medications at initiation, patients who were adherent above these levels had a 25% lower risk of flare for ADA (HR: 0.75, 95%CI: 0.67-0.83, P<0.01) and 41% lower risk for CZP (HR: 0.59, 95%CI: 0.46-0.76, P<0.01). CONCLUSIONS: Patients who delay refills >2 days on average every 2 weeks of their subcutaneous biologics have significantly increased risk of flare. Further studies to improve adherence among those patients who consistently delay medication use are necessary.
OBJECTIVES: In patients with inflammatory bowel disease (IBD) using biological therapy, non-adherence leads to anti-drug antibody formation and reduced effectiveness. Little is known about the optimal level of adherence in IBD patients on biologic therapy. We aimed to identify the association between adherence and disease flare and determine an optimal level of adherence. METHODS: We analyzed claims data for IBD patients prescribed adalimumab (ADA) and certolizumab (CZP) from the Truven Health MarketScan Commercial Claims and Encounters database from 2009 to 2013. Adherence was calculated using the medication possession ratio (MPR) from initiation until flare occurrence. A disease flare was defined as any hospitalization or new steroid prescription>90-days after drug initiation. The optimal MPR was determined using log-rank testing. The association between the optimal MPR and flare was assessed using multivariable Cox-Proportional hazards ratio. RESULTS: There were 6,048 patients who were prescribed ADA (n=5,325) or CZP (n=723) for IBD. The average age was 41 years (±15) and 54% were female. The optimal MPR identified was 0.86 for ADA and 0.87 for CZP; 24% of the patients were below this level. Adjusting for age, gender, and concomitant medications at initiation, patients who were adherent above these levels had a 25% lower risk of flare for ADA (HR: 0.75, 95%CI: 0.67-0.83, P<0.01) and 41% lower risk for CZP (HR: 0.59, 95%CI: 0.46-0.76, P<0.01). CONCLUSIONS: Patients who delay refills >2 days on average every 2 weeks of their subcutaneous biologics have significantly increased risk of flare. Further studies to improve adherence among those patients who consistently delay medication use are necessary.
Authors: Dana P Goldman; Geoffrey F Joyce; Grant Lawless; William H Crown; Vincent Willey Journal: Health Aff (Millwood) Date: 2006 Sep-Oct Impact factor: 6.301
Authors: R W Stidham; T C H Lee; P D R Higgins; A R Deshpande; D A Sussman; A G Singal; B J Elmunzer; S D Saini; S Vijan; A K Waljee Journal: Aliment Pharmacol Ther Date: 2014-02-09 Impact factor: 8.171
Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts Journal: N Engl J Med Date: 2010-04-15 Impact factor: 91.245
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Marcia Valenstein; Laurel A Copeland; Frederic C Blow; John F McCarthy; John E Zeber; Leah Gillon; C Raymond Bingham; Thomas Stavenger Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Amanda M Kibbons; Megan Peter; Josh DeClercq; Leena Choi; Jacob Bell; Jacob Jolly; Elizabeth Cherry; Bassel Alhashemi; Nisha B Shah; Autumn D Zuckerman Journal: Drugs Real World Outcomes Date: 2020-09-21
Authors: Amanda M Kibbons; Megan Peter; Josh DeClercq; Leena Choi; Jacob Bell; Jacob Jolly; Elizabeth Cherry; Bassel Alhashemi; Nisha B Shah; Autumn D Zuckerman Journal: Drugs Real World Outcomes Date: 2020-12
Authors: Nisha B Shah; Jennifer Haydek; James Slaughter; Jonathan R Ashton; Autumn D Zuckerman; Rochelle Wong; Francesca Raffa; Ailish Garrett; Caroline Duley; Kim Annis; Julianne Wagnon; Lawrence Gaines; Robin Dalal; Elizabeth Scoville; Dawn B Beaulieu; David Schwartz; Sara N Horst Journal: Inflamm Bowel Dis Date: 2020-01-06 Impact factor: 5.325
Authors: Christian Rhudy; Courtney L Perry; Michael Singleton; Jeffery Talbert; Terrence A Barrett Journal: Aliment Pharmacol Ther Date: 2021-01-26 Impact factor: 8.171
Authors: Anava A Wren; Rachel Bensen; Lindsay Sceats; Melody Dehghan; Helen Yu; Jessie J Wong; Donna MacIsaac; Zachary M Sellers; Cindy Kin; K T Park Journal: Inflamm Bowel Dis Date: 2018-09-15 Impact factor: 7.290
Authors: Johannes P D Schultheiss; Sandra Altena; Max R Clevers; Dominique Baas; Bindia Jharap; Herma H Fidder Journal: Dig Dis Sci Date: 2020-06-16 Impact factor: 3.199